VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
LGVN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
LGVNLongeveron Inc.
$1.92$6M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
LGVN logo

Longeveron Inc.

LGVN
NASDAQ · Cell & Gene Therapy
$1.92
At close - Nov 18, 4:00 PM EST - USD
Market Cap$6M
P/E-0.3x
52W High$12.30
Volume82K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q1

Persistent Clinical Burn Outpaces Revenue Growth Potential

Longeveron faces a precarious fundamental outlook as its LOMECEL-B therapy remains in high-cost clinical development without a stable commercial revenue stream.

GrowthContracting
ProfitabilityNegative
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

LGVN price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

4/12 Beats

EPS beat 4 of last 12 quarters

02

Valuation risk

-101% Peers

P/E is 101% below peer median

03

Market leadership

RS 37 · Lag

Laggard (Underperforming 63% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Nov 12

Market performance

Price History →

Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
LGVN-67.62%
S&P 500 (^GSPC)+6.88%
1-Year Return
LGVN+200.00%
S&P 500 (^GSPC)+10.62%
3-Year Return
LGVN-90.00%
S&P 500 (^GSPC)+54.05%
5-Year Return
LGVN-97.21%
S&P 500 (^GSPC)-4.93%

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$1M-49.9% YoY
Net income FY25
-$23M-42.1% YoY
Free cash flow FY25
-$19M-27.1% YoY
Operating margin FY25
-1942.2%-1251.5 pts YoY
ROIC (FY25)-588.1%
Avg ROIC 5Y-264%
ROE (TTM)-243.3%
Piotroski Score2 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate4/12 (33%)
Revenue Beat Rate6/12 (50%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q3 2026Latest
Aug 12, 2026
-$0.19-8.6%
vs -$0.17
$287,000-12.0%
vs $326,000
Q2 2026
May 13, 2026
-$0.19+0.0%
vs -$0.19
$398,000+19.0%
vs $334,500
Q2 2026
Mar 17, 2026
-$0.22+47.6%
vs -$0.42
$365,000+230.8%
vs $110,333
Q4 2025
Nov 4, 2025
-$0.39-50.0%
vs -$0.26
$137,000+24.2%
vs $110,330
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
GlobeNewsWire·6d ago
Longeveron Announces 2026 Third Quarter Financial Results and Provides Business Update

Following reporting of results for the ELPIS II Phase 2b clinical trial, the Company has requested a meeting with the FDA to review the results to determine potential next steps for the HLHS development program The Company has initiated a process to review all strategic options with a goal of maximizing stockholder value and has implemented cash conservation measures to optimize cost containment Lucid Capital Markets retained as the Company's financial advisor to explore potential strategic opportunities, including a potential business combination MIAMI, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today reported financial results for the quarter ended September 30, 2026 and provided a business update. “With ELPIS II results now available, we have requested a meeting with the FDA to determine potential next steps for the HLHS development program,” said Stephen H.

GlobeNewsWire·Oct 28, 2026
Longeveron Announces Engagement of Lucid Capital Markets

MIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (the “Company”) (NASDAQ: LGVN), today announced that the Company has retained Lucid Capital Markets, LLC as the Company's financial advisor to explore potential strategic opportunities, including a potential business combination. About Longeveron Inc. Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs.

GlobeNewsWire·Oct 26, 2026
Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)

ELPIS II 2 Data in HLHS Selected for Late-Breaking Science Program Podium Presentation in the American Heart Association's (AHA) 2026 Scientific Sessions As previously reported, the ELPIS II trial did not meet the primary endpoint of increase in right ventricular ejection fraction (RVEF) at month 12 and the Company planned to continue analysis of additional data Additional analysis demonstrates an important pre-specified secondary clinical outcome endpoint, major adverse cardiac events (MACE), achieved statistical significance with 8 events in the standard of care arm versus 1 in the laromestrocel treatment arm (P=0.043) Laromestrocel was associated with fewer adjudicated clinical and safety events than the standard of care arm The Company believes the results suggest that laromestrocel may have the potential to meaningfully improve clinical outcomes of children with HLHS undergoing Stage II surgical palliation MIAMI, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced updated results from ELPIS II following planned additional analysis conducted by the Company and the National Institutes of Health (NIH) funded trial investigators. ELPIS II is the Company's Phase 2b clinical trial evaluating its investigational stem cell therapy laromestrocel as an adjunct to Stage 2 palliative surgery in 40 infants with hypoplastic left heart syndrome (HLHS).

GlobeNewsWire·Sep 30, 2026
Longeveron to Participate in Three Longevity/Aging Investment Conferences

MIAMI, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in three upcoming Longevity/Aging investment conferences.

Filtered for Longeveron Inc.More Headlines
04

Compare before deciding

Benchmark LGVN against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Longeveron Inc. (LGVN)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
LGVN logoLGVNLongeveron Inc.Current
$1.92$5.84M-0.28-49.87%-1921.72%-243.26%—
MESO logoMESOMesoblast Limited
$11.64$1.51B-26.27602.33%-47.82%-10.06%—
NKTR logoNKTRNektar Therapeutics
$34.42$1.18B-6.64-43.89%-339.67%-29.31%—
BCLI logoBCLIBrainstorm Cell Therapeutics Inc.
$0.90$9.92M-0.81————
PLUR logoPLURPluri Inc.
$0.94$8.41M-0.24-23.95%-2265.14%——
FATE logoFATEFate Therapeutics, Inc.
$1.05$122.39M-1.04-51.24%-2619.64%-73.92%—

Compare LGVN vs Peers

Longeveron Inc. (LGVN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs MESO

Most directly comparable listed peer for LGVN.

Scale Benchmark

vs IQV

Larger-name benchmark to compare LGVN against a more recognizable public peer.

Peer Set

Compare Top 5

vs MESO, NKTR, BCLI, PLUR

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

LGVN SEC Filings & Documents

Longeveron Inc. (LGVN) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Aug 24, 2026·SEC

Material company update

Aug 19, 2026·SEC

Material company update

Aug 12, 2026·SEC

10-K Annual Reports

2
FY 2026

Mar 17, 2026·SEC

FY 2025

Feb 28, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

Aug 12, 2026·SEC

FY 2026

May 13, 2026·SEC

FY 2025

Nov 4, 2025·SEC

Get notified when LGVN posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

LGVN Frequently Asked Questions

Longeveron Inc. (LGVN) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Longeveron Inc.'s revenue?

Longeveron Inc. (LGVN) reported $1.2M in revenue over the trailing twelve months. Revenue was $1.2M in fiscal year 2025. That is 44% less than the $2.1M of fiscal year 2018.

How fast is Longeveron Inc. growing?

Longeveron Inc. (LGVN) revenue fell by 18.9% over the trailing twelve months, compared with the twelve months before.

Is LGVN profitable?

No. Longeveron Inc. (LGVN) reported a net loss of $22.4M over the trailing twelve months.

Dividend & Returns
What is LGVN's return on equity?

Longeveron Inc. (LGVN) had a return on equity (ROE) of -243.3% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Longeveron Inc.'s free cash flow?

Longeveron Inc. (LGVN) had negative free cash flow of $18.2M over the trailing twelve months.

What if you invested $1,000 in LGVN back in 2018?

Total return calculator · dividends reinvested · 8+ years of data

See returns →